Moderna Stock Doubles on Cancer Breakthrough: Here’s What It Means
A Phase 3 win against the standard of care sent the biotech's shares up 131% and left short sellers down $4.8 billion.
- 来源
- Decrypt
- 发布时间
- 2026-08-19 16:54 UTC
- 缓存更新
- 2026-08-19 17:01 UTC
本页仅展示标题、摘要与来源信息，完整内容请访问原新闻源。
打开原文 ↗查看手续费